Abstract Treatment resistance affects 20–60% of patients with psychiatric disorders; and is
associated with increased healthcare burden and costs up to ten-fold higher relative to …

Background Major depressive disorder (MDD) is a global public health concern. In
particular, treatment-resistant depression (TRD) represents a key unmet need in the …

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify
and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are …

Anhedonia is one of the core symptoms of major depressive disorder (MDD), which is often
inadequately treated by traditional antidepressants. The modern framework of anhedonia …

Objectives Obesity is associated with increased risk of depression, but the extent to which
this association is symptom-specific is unknown. We examined the associations of …

Abstract Treatment-resistant depression (TRD) is a major contributor to the disability caused
by major depressive disorder (MDD). Primary care electronic health records provide an …

We describe evidence for dissociable roles of the medial and lateral orbitofrontal cortex
(OFC) in major depressive disorder (MDD) from structure, functional activation, functional …

Disruption in reciprocal connectivity between the right anterior insula and the left
dorsolateral prefrontal cortex is associated with depression and may be a target for …

Despite significant advances in pharmacological and non-pharmacological treatments,
mood disorders remain a significant source of mental capital loss, with high rates of …

Objective: No universal definition for treatment-resistant depression (TRD) exists. This lack
of consensus reduces the generalizability of study findings and limits the ability to study …